Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study.

Ramsenthaler C, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ.

Palliat Med. 2019 May;33(5):541-551. doi: 10.1177/0269216319833588.

PMID:
31060467
2.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.

Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.

3.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.

4.

Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.

Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ.

Eur J Haematol. 2016 Nov;97(5):416-429. doi: 10.1111/ejh.12790. Epub 2016 Sep 6. Review.

PMID:
27528496
5.

The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.

Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ.

BMC Cancer. 2016 Jul 7;16:427. doi: 10.1186/s12885-016-2410-2.

6.

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.

Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):519-30. doi: 10.1016/j.clml.2015.05.007. Epub 2015 Jun 6.

PMID:
26149712
7.

Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS).

Osborne TR, Ramsenthaler C, Schey SA, Siegert RJ, Edmonds PM, Higginson IJ.

BMC Cancer. 2015 Apr 14;15:280. doi: 10.1186/s12885-015-1261-6.

8.

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.

Song KW, Dimopoulos MA, Weisel KC, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Monzini MS, Zaki M, Jacques C, San Miguel J.

Haematologica. 2015 Feb;100(2):e63-7. doi: 10.3324/haematol.2014.112557. Epub 2014 Nov 25. No abstract available.

9.

Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life.

Osborne TR, Ramsenthaler C, de Wolf-Linder S, Schey SA, Siegert RJ, Edmonds PM, Higginson IJ.

BMC Cancer. 2014 Jul 9;14:496. doi: 10.1186/1471-2407-14-496.

10.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.

Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.

PMID:
24007748
11.

A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1.

Bano G, Mir F, Beharry N, Wilson P, Hodgson S, Schey S.

Int J Endocrinol Metab. 2013 Winter;11(1):52-6. doi: 10.5812/ijem.6898. Epub 2012 Dec 21.

12.

What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools.

Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ.

Eur J Haematol. 2012 Dec;89(6):437-57. doi: 10.1111/ejh.12012. Epub 2012 Oct 26. Review.

PMID:
22985406
13.

Rituximab and thalidomide combination therapy for Castleman disease.

Ramasamy K, Gandhi S, Tenant-Flowers M, Ceesay M, Corderoy S, Marcus R, Schey S.

Br J Haematol. 2012 Aug;158(3):421-3. doi: 10.1111/j.1365-2141.2012.09157.x. Epub 2012 May 14. No abstract available.

PMID:
22583139
14.

Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.

Ramasamy K, Khatun H, Macpherson L, Caley MP, Sturge J, Mufti GJ, Schey SA, Calle Y.

Br J Haematol. 2012 Jun;157(5):564-79. doi: 10.1111/j.1365-2141.2012.09103.x. Epub 2012 Mar 20.

PMID:
22428569
15.

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.

Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S.

Br J Haematol. 2011 Dec;155(5):632-4. doi: 10.1111/j.1365-2141.2011.08754.x. Epub 2011 Jun 21. No abstract available.

PMID:
21689088
16.

Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.

Ramasamy K, Mahmood S, Lim Z, Corderoy S, Devereux S, Mufti GJ, Pagliuca A, Schey S.

Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):242-5. doi: 10.1016/j.clml.2011.03.004. Epub 2011 Apr 8.

PMID:
21575930
17.

Pomalidomide therapy for myeloma.

Schey S, Ramasamy K.

Expert Opin Investig Drugs. 2011 May;20(5):691-700. doi: 10.1517/13543784.2011.567265. Epub 2011 Mar 18. Review.

PMID:
21413906
18.

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE.

Br J Haematol. 2010 Aug;150(3):326-33. doi: 10.1111/j.1365-2141.2010.08250.x. Epub 2010 Jun 10.

PMID:
20553268
19.

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA.

Br J Haematol. 2008 Apr;141(1):41-51. doi: 10.1111/j.1365-2141.2008.07013.x.

PMID:
18324965
20.

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.

Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, Davies FE.

Br J Haematol. 2007 May;137(3):268-9. No abstract available.

PMID:
17408469

Supplemental Content

Loading ...
Support Center